Chen Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chen Zhang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Chunyan Ji
Department of Hematology, Qilu Hospital of Shandong University, Jinan, China
1 shared publication - Daoxin Ma
Department of Hematology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China
1 shared publication - Fang Zhong
Department of Endocrinology and Metabolism, Shandong Provincial Hospital affiliated with Shandong University, Jinan, P. R. China
1 shared publication - Jinting Liu
Department of Hematology, Qilu Hospital of Shandong University, Jinan, P. R. China
1 shared publication - Ruiqing Wang
Department of Hematology, Qilu Hospital of Shandong University, Jinan, P. R. China
1 shared publication - Tao Sun
Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 9 May 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-18
Gut microbiota regulates acute myeloid leukaemia via alteration of intestinal barrier function mediated by butyrate
The gut microbiota has been linked to many cancers, yet its role in acute myeloid leukaemia (AML) progression remains unclear. Here, we show decreased diversity in the gut microbiota of AML patients or murine models. Gut microbiota dysbiosis induced by antibiotic treatment accelerates murine AML progression while faecal microbiota transplantation reverses this process. Butyrate produced by the gut microbiota (especially Faecalibacterium) significantly decreases in faeces of AML patients, while gavage with butyrate or Faecalibacterium postpones murine AML progression. Furthermore, we find the intestinal barrier is damaged in mice with AML, which accelerates lipopolysaccharide (LPS) leakage into the blood. The increased LPS exacerbates leukaemia progression in vitro and in vivo. Butyrate can repair intestinal barrier damage and inhibit LPS absorption in AML mice. Collectively, we demonstrate that the gut microbiota promotes AML progression in a metabolite-dependent manner and that targeting the gut microbiota might provide a therapeutic option for AML.
- 9 May 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-18
Top Cited PapersOpen AccessGut microbiota regulates acute myeloid leukaemia via alteration of intestinal barrier function mediated by butyrate
The gut microbiota has been linked to many cancers, yet its role in acute myeloid leukaemia (AML) progression remains unclear. Here, we show decreased diversity in the gut microbiota of AML patients or murine models. Gut microbiota dysbiosis induced by antibiotic treatment accelerates murine AML progression while faecal microbiota transplantation reverses this process. Butyrate produced by the gut microbiota (especially Faecalibacterium) significantly decreases in faeces of AML patients, while gavage with butyrate or Faecalibacterium postpones murine AML progression. Furthermore, we find the intestinal barrier is damaged in mice with AML, which accelerates lipopolysaccharide (LPS) leakage into the blood. The increased LPS exacerbates leukaemia progression in vitro and in vivo. Butyrate can repair intestinal barrier damage and inhibit LPS absorption in AML mice. Collectively, we demonstrate that the gut microbiota promotes AML progression in a metabolite-dependent manner and that targeting the gut microbiota might provide a therapeutic option for AML.